| RSS
Business center
Office
Post trade leads
Post
Rank promotion
Ranking
 
You are at: Home » News » internal »

Nuevolution A/S Appoints Professor Mark C. Genovese, MD as Advisor to Support the Companies’ Pre-Cli

Increase font size  Decrease font size Date:2015-11-27   Views:405

Copenhagen, Denmark, November 18, 2015 / B3C newswire / -- Nuevolution is pleased to announce that Dr. Mark Genovese has joined as Scientific Advisor. Mark brings a vast knowledge and expertise within the field of inflammatory diseases to Nuevolution as well as a profound understanding of pre-clinical and clinical research, supporting the commercial value of Nuevolution’s program pipeline.

Dr. Genovese serves as a Professor of Medicine and is Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center. He established a clinical research program at Stanford University that is focused on bench-to-bedside translational medicine in autoimmune diseases and has designed and participated in many trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis.

 “We are happy to have initiated our collaboration with Mark, who is a leader in the field of clinical immunology, and that he has accepted to join our Advisory Panel, said Thomas Franch, CSO of Nuevolution. “We are certain that Mark’s expertise will help us to accelerate our immunology projects further to meet our ambitions of providing novel treatment options for inflammatory diseases”.


About Nuevolution
Nuevolution is a leading small molecule drug discovery biotech company founded in 2001, and based in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The company has developed its proprietary drug discovery platform Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery platform for both identification and optimization of hit to candidate compounds. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating the identification of potent drug leads at unprecedented speed and scale.

Nuevolution has also entered into agreements with Merck & Co. (MSD), Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into technology licensing agreements with Nuevolution. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution.

Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital and Industrifonden. For further information about Nuevolution A/S, please visit our website: www.nuevolution.com

 
 
[ Search ]  [ ]  [ Email ]  [ Print ]  [ Close ]  [ Top ]

 
Total:0comment(s) [View All]  Related comment

 
Recomment
Popular
 
 
Home | About | Service | copyright | agreement | contact | about | SiteMap | Links | GuestBook | Ads service | 京ICP 68975478-1
Tel:+86-10-68645975           Fax:+86-10-68645973
E-mail:yaoshang68@163.com     QQ:1483838028